ArticleResearch square2026
Loss of endothelial cell FAK represses cisplatin-induced vascular senescence in distal niches to reduce lung metastatic burden.
Article in Research square, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Platinum-based chemotherapy is widely used to treat non-small cell lung cancer: however, intrathoracic metastasis remains a major clinical challenge associated with increased morbidity. While chemotherapy is generally viewed as acting directly on tumour cells, it can also reprogramme the tumour microenvironment, including vascular endothelial cells. Here, we identify endothelial cell focal adhesion kinase (FAK) as a regulator of cisplatin-induced vascular stress responses that promote metastatic seeding in the lung. Using inducible endothelial cell-specific FAK loss- and endothelial cell-specific kinase-dead mouse models, we show that endothelial cell FAK is required for cisplatin-enhanced lung metastasis. In the pre-metastatic lung, cisplatin induces endothelial cell DNA damage and FAK-dependent transcriptional reprogramming enriched for p53-responsive, stress-adaptive, and senescence-associated genes. Cisplatin treatment also promotes an endothelial cell FAK-dependent secretory and adhesive state increasing tumour cell binding and metastasis seeding in the lung. Mechanistically, cisplatin triggers a transient nuclear accumulation of FAK, where kinase activity supports early ATM signaling and DNA repair. Overall, our data indicate that targeting endothelial cell FAK suppresses these responses and reduces cisplatin-induced lung metastasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.